News › Industry News, Patient Care, Practice Management

FDA Announces Semaglutide Shortage Resolved

February 24, 2025

On February 21, 2025, the FDA announced that the shortage of semaglutide has been resolved due to increased manufacturing capacity. This follows the recent resolution of the tirzepatide shortage (link here). To prevent disruption to patient care, the FDA will not take enforcement action against compounders for certain violations related to compounding semaglutide until April 22, 2025, for pharmacies and until May 22, 2025, for outsourcing facilities. The FDA is also monitoring the availability of other GLP-1 medications, including dulaglutide and liraglutide, which remain in shortage.

In the short term, before the FDA’s deadlines, these compounded medications should still be available. However, practices should start reviewing and updating their weight loss programs to prepare for after these deadlines pass. AmSpa had this article and ByrdAdatto had this article on things to consider when the shortages are over. You may also want to speak with an attorney for guidance on your particular situation.  

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement